-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA declines approval of Summit Therapeutics' ivonescimab for lung cancer

PUBT·11/15/2026 12:00:30
Listen to the news
FDA declines approval of Summit Therapeutics' ivonescimab for lung cancer
  • Summit Therapeutics received an FDA complete response letter blocking ivonescimab with chemotherapy for previously treated advanced lung cancer in its current application.
  • Reported Phase III HARMONi results showed delayed disease progression but no statistically significant overall survival improvement, which the FDA deemed insufficient for approval.
  • The company plans to continue ivonescimab development across multiple cancers despite the regulatory setback.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611150700BIZWIRE_USPR_____20261115_BW117181) on November 15, 2026, and is solely responsible for the information contained therein.